Chemistry:PRX-03140

Short description: Chemical compound

PRX-03140

Clinical data
ATC code	None
Identifiers
IUPAC name 4-hydroxy-7-isopropyl-6-oxo-N-[3-(1-piperidinyl)propyl]-6,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
CAS Number	869493-21-0
PubChem CID	54677674
ChemSpider	21377738
UNII	7QGN8QXG7I
Chemical and physical data
Formula	C19H27N3O3S
Molar mass	377.50 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)N1C(=O)\C(=C(\O)c2ccsc12)C(=O)NCCCN3CCCCC3
InChI InChI=1S/C19H27N3O3S/c1-13(2)22-18(25)15(16(23)14-7-12-26-19(14)22)17(24)20-8-6-11-21-9-4-3-5-10-21/h7,12-13,23H,3-6,8-11H2,1-2H3,(H,20,24) Key:SCHKZZSVELPJKU-UHFFFAOYSA-N

PRX-03140 is a partial agonist (18% relative to 5-HT) of the 5-HT₄ receptor that was developed by EPIX Pharmaceuticals for Alzheimer's disease.

Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts . In 2009, Epix was in the process of asset liquidation due to insufficient funds to stay afloat. Nanotherapeutics, Inc. acquired the product in 2010 conducting one clinical study in PTSD patients. In 2018 the product was transferred to Nanoshift, LLC. Nanoshift LLC and Nanopharmaceutics, Inc. (www.nanopharmaceutics.com) continue to support clinical studies. It has been tested in six Phase 1 and Phase 2 clinical trials.